company background image

Repligen NasdaqGS:RGEN Stock Report

Last Price


Market Cap







04 Oct, 2022


Company Financials +
RGEN fundamental analysis
Snowflake Score
Future Growth3/6
Past Performance5/6
Financial Health6/6

RGEN Stock Overview

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally.

Repligen Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Repligen
Historical stock prices
Current Share PriceUS$213.55
52 Week HighUS$306.98
52 Week LowUS$137.21
1 Month Change1.53%
3 Month Change26.77%
1 Year Change-21.02%
3 Year Change183.71%
5 Year Change469.92%
Change since IPO2,035.50%

Recent News & Updates

Oct 03
Is Repligen (NASDAQ:RGEN) A Risky Investment?

Is Repligen (NASDAQ:RGEN) A Risky Investment?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Sep 27

Repligen: Now Best Biotech Nearby Cap-Gain Prospect

Summary Biotech stocks’ bad investment reputations often (not always) come from failed lab tests. But today’s opportunity comes from overenergetic market correction. A week ago I highlighted BGNE as the most opportune biotech stock for near-term capital gain. Forecast: +22% up, maybe -14% on the way getting there. BGNE got to -12% now, Friday, but RGEN outdid it, plummeting -18% in a week. And RGEN has a reputation of realizing its market-maker upside price targets - and more. Now RGEN offers+25% (accomplished) to BGNE’s +14%, and in 32 market days (6 weeks) instead of 42 (2 months). Adjusted for odds, 80 bp/day instead of 21bp/day. So, swap BGNE into RGEN? Nah, BGNE still offers 116% CAGR; keep it and find another sell candidate to fund the RGEN buy. The primary focus of this article is Repligen Corporation (RGEN). Investment Thesis 21st Century paces of change in technology and rational behavior (not of emotional reactions) seriously disrupts the commonly accepted productive investment strategy of the 20th century. One required change is the shortening of forecast horizons, with a shift from the multi-year passive approach of buy&hold to the active strategy of specific price-change target achievement or time-limit actions, with reinvestment set to new nearer-term targets. That change avoids the irretrievable loss of invested time spent destructively by failure to recognize shifting evolution like the cases of IBM, Kodak, GM, Xerox, GE and many earlier others. It recognizes the progress in medical, communication and information technologies and enjoys their operational benefits already present in extended lifetimes, trade-commission-free investments, and coming benefits in transportation utilization and energy usage. But it requires the ability to make valid direct comparisons of value between investment reward prospects and risk exposures in the uncertain future. Since uncertainty expands as the future dimension increases, shorter forecast horizons are a means of improving the reward-to-risk comparison. That shortening is now best attended at the investment entry point by knowing Market-Maker expectations for coming prices. When reached, their updates are then reintroduced at the exit/reinvestment point and the term of expectations for the required coming comparisons are recognized as the decision entry point to move forward. The MM's constant presence, extensive global communications and human resources dedicated to monitoring industry-focused competitive evolution sharpens MM price expectations, essential to their risk-avoidance roles. Their roles require firm capital be only temporarily risk-exposed, so they get hedged by derivative-securities deals to avoid undesired price changes. The deals' prices and contracts provide a window to MM price expectations. Information technology via the internet makes investment monitoring and management time and attention efficient despite its increase in frequency. Once an investment choice is made and buy transaction confirmation is received, a target-price GTC sell order for the confirmed number of shares at the target price or better should be placed to ensure realization. Keeping trade actions entered through the internet on your lap/desk-top or cell phone should avoid trade commission charges. Your broker's internal system should keep you informed of your account's progress. Your own private calendar record should be kept noting the date 63 market days (or 91 calendar days) beyond the trade's confirmation date as a time-limit alert to check if the GTC order has not been executed. If not, then start your decision process of exit and reinvestment. The 3-months time limit is what we find to be a good choice, but may be extended a month at a time if desired. Beyond 5-6 months further investments of time start to work against the process and are not recommended. For investments guided by this article or by others target sell prices will always be found here as the high price in the MM forecast range. Description of Equity Subject Company Repligen Corporation develops and commercializes bio-processing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts. Source: Yahoo Finance Yahoo Finance These growth estimates have been made by and are collected from Wall Street analysts to suggest what conventional methodology currently produces. The typical variations across forecast horizons of different time periods illustrate the difficulty of making value comparisons when the forecast horizon is not clearly defined. Risk and Reward Balances Among Biotech Developer Competitors Figure 1 The risk dimension is of actual price drawdowns at their most extreme point while being held in previous pursuit of upside rewards similar to the ones currently being seen. They are measured on the red vertical scale. Reward expectations are measured on the green horizontal scale. Both scales are of percent change from zero to 25%. Any stock or ETF whose present risk exposure exceeds its reward prospect will be above the dotted diagonal line. Capital-gain-attractive to-buy issues are in the directions down and to the right. Our principal interest is in RGEN at location [5], close to the right edge of the green horizontal reward scale, and well within the 5 to 1 reward~risk area. A "market index" norm of reward~risk tradeoffs is offered by SPY at [25]. Most appealing by this Figure 1 view for wealth-building investors appears to be RGEN. Comparable features of Biotech Competitors The Figure 1 map provides a good visual comparison of the two most important aspects of every equity investment in the short term. There are other aspects of comparison which this map sometimes does not communicate well, particularly when general market perspectives like those of SPY are involved. Where questions of "how likely' are present other comparative tables, like Figure 2, may be useful. Yellow highlighting of the table's cells emphasize factors important to securities valuations and the security RGEN of most promising of near capital gain as ranked in column [R]. Symbol similarity prompts the caution-highlighted data row of REGN, a different biotech stock. Figure 2 Why do All This Math? Figure 2's purpose is to attempt universally comparable answers, stock by stock, of a) How BIG the prospective price gain payoff may be, b) how LIKELY the payoff will be a profitable experience, c) how SOON it may happen, and d) what price draw-down RISK may be encountered during its active holding period. Readers familiar with our analysis methods after quick examination of Figure 2 may wish to skip to the next section viewing price range forecast trends for RGEN. Column headers for Figure 2 define investment-choice preference elements for each row stock whose symbol appears at the left in column [A]. The elements are derived or calculated separately for each stock, based on the specifics of its situation and current-day MM price-range forecasts. Data in red numerals are negative, usually undesirable to "long" holding positions. Table cells with yellow fills are of data for the stocks of principal interest and of all issues at the ranking column, [R]. The price-range forecast limits of columns [B] and [C] get defined by MM hedging actions to protect firm capital required to be put at risk of price changes from volume trade orders placed by big-$ "institutional" clients. [E] measures potential upside risks for MM short positions created to fill such orders, and reward potentials for the buy-side positions so created. Prior forecasts like the present provide a history of relevant price draw-down risks for buyers. The most severe ones actually encountered are in [F], during holding periods in effort to reach [E] gains. Those are where buyers are emotionally most likely to accept losses. The Range Index [G] tells where today's price lies relative to the MM community's forecast of upper and lower limits of coming prices. Its numeric is the percentage proportion of the full low to high forecast seen below the current market price. [H] tells what proportion of the [L] sample of prior like-balance forecasts have earned gains by either having price reach its [B] target or be above its [D] entry cost at the end of a 3-month max-patience holding period limit. [ I ] gives the net gains-losses of those [L] experiences. What makes RGEN most attractive in the group at this point in time is its ability to produce capital gains most consistently at its present operating balance between share price risk and reward at the Range Index [G]. At a RI of 1, today's price is at the bottom of its forecast range, with price expectations to the upside the entirety of the forecast. Not our expectations, but those of Market-Makers acting in support of Institutional Investment organization clients building the values of their typical multi-billion-$ portfolios. Credibility of the [E] upside prospect as evidenced in the [I] payoff at +25.6% is shown in [N]. Further Reward~Risk tradeoffs involve using the [H] odds for gains with the 100 - H loss odds as weights for N-conditioned [E] and for [F], for a combined-return score [Q]. The typical position holding period [J] on [Q] provides a figure of merit [fom] ranking measure [R] useful in portfolio position preferencing. Figure 2 is row-ranked on [R] among alternative candidate securities, with RGEN in top rank.

Sep 19

Repligen partners with DRS daylight solutions

Repligen (NASDAQ:RGEN) said it had entered into a partnership and exclusive license agreement with DRS Daylight Solutions to expand the use of mid-infrared (mid-IR) technology in the bioprocessing market. Under the deal, Repligen will commercialize Culpeo, as well as develop future products and technologies in partnership with DRS Daylight Solutions. Both companies will focus on expanding the portfolio of Quantum Cascade Laser mid-IR (QCL-IR) and integrating these solutions into Repligen Chromatography and Filtration systems.

Sep 19
When Should You Buy Repligen Corporation (NASDAQ:RGEN)?

When Should You Buy Repligen Corporation (NASDAQ:RGEN)?

Repligen Corporation ( NASDAQ:RGEN ) led the NASDAQGS gainers with a relatively large price hike in the past couple of...

Shareholder Returns

RGENUS Life SciencesUS Market

Return vs Industry: RGEN exceeded the US Life Sciences industry which returned -28.8% over the past year.

Return vs Market: RGEN matched the US Market which returned -20% over the past year.

Price Volatility

Is RGEN's price volatile compared to industry and market?
RGEN volatility
RGEN Average Weekly Movement8.7%
Life Sciences Industry Average Movement9.7%
Market Average Movement6.8%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: RGEN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: RGEN's weekly volatility (9%) has been stable over the past year.

About the Company

19811,852Tony Hunt

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company’s chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes.

Repligen Fundamentals Summary

How do Repligen's earnings and revenue compare to its market cap?
RGEN fundamental statistics
Market CapUS$11.85b
Earnings (TTM)US$159.43m
Revenue (TTM)US$778.77m


P/E Ratio


P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
RGEN income statement (TTM)
Cost of RevenueUS$318.23m
Gross ProfitUS$460.54m
Other ExpensesUS$301.11m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date


Earnings per share (EPS)2.87
Gross Margin59.14%
Net Profit Margin20.47%
Debt/Equity Ratio15.7%

How did RGEN perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.


Is RGEN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 3/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for RGEN?

Other financial metrics that can be useful for relative valuation.

RGEN key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue15x
Enterprise Value/EBITDA45.6x
PEG Ratio4x

Price to Earnings Ratio vs Peers

How does RGEN's PE Ratio compare to its peers?

RGEN PE Ratio vs Peers
The above table shows the PE ratio for RGEN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average41.2x
TECH Bio-Techne
QGEN Qiagen
CRL Charles River Laboratories International
RGEN Repligen

Price-To-Earnings vs Peers: RGEN is expensive based on its Price-To-Earnings Ratio (74.3x) compared to the peer average (41.2x).

Price to Earnings Ratio vs Industry

How does RGEN's PE Ratio compare vs other companies in the US Life Sciences Industry?

Price-To-Earnings vs Industry: RGEN is expensive based on its Price-To-Earnings Ratio (74.3x) compared to the US Life Sciences industry average (23.8x)

Price to Earnings Ratio vs Fair Ratio

What is RGEN's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

RGEN PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio74.3x
Fair PE Ratio29.9x

Price-To-Earnings vs Fair Ratio: RGEN is expensive based on its Price-To-Earnings Ratio (74.3x) compared to the estimated Fair Price-To-Earnings Ratio (29.9x).

Share Price vs Fair Value

What is the Fair Price of RGEN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: RGEN ($213.55) is trading below our estimate of fair value ($279.09)

Significantly Below Fair Value: RGEN is trading below fair value by more than 20%.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Future Growth

How is Repligen forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?

Future Growth Score


Future Growth Score 3/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: RGEN's forecast earnings growth (18.4% per year) is above the savings rate (1.9%).

Earnings vs Market: RGEN's earnings (18.4% per year) are forecast to grow faster than the US market (14.7% per year).

High Growth Earnings: RGEN's earnings are forecast to grow, but not significantly.

Revenue vs Market: RGEN's revenue (16.1% per year) is forecast to grow faster than the US market (7.6% per year).

High Growth Revenue: RGEN's revenue (16.1% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: RGEN's Return on Equity is forecast to be low in 3 years time (10%).

Discover growth companies

Past Performance

How has Repligen performed over the past 5 years?

Past Performance Score


Past Performance Score 5/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: RGEN has high quality earnings.

Growing Profit Margin: RGEN's current net profit margins (20.5%) are higher than last year (19.7%).

Past Earnings Growth Analysis

Earnings Trend: RGEN's earnings have grown significantly by 47.4% per year over the past 5 years.

Accelerating Growth: RGEN's earnings growth over the past year (59.5%) exceeds its 5-year average (47.4% per year).

Earnings vs Industry: RGEN earnings growth over the past year (59.5%) exceeded the Life Sciences industry 15.6%.

Return on Equity

High ROE: RGEN's Return on Equity (8.8%) is considered low.

Discover strong past performing companies

Financial Health

How is Repligen's financial position?

Financial Health Score


Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: RGEN's short term assets ($976.0M) exceed its short term liabilities ($423.5M).

Long Term Liabilities: RGEN's short term assets ($976.0M) exceed its long term liabilities ($216.0M).

Debt to Equity History and Analysis

Debt Level: RGEN has more cash than its total debt.

Reducing Debt: RGEN's debt to equity ratio has reduced from 49.8% to 15.7% over the past 5 years.

Debt Coverage: RGEN's debt is well covered by operating cash flow (49.7%).

Interest Coverage: RGEN's interest payments on its debt are well covered by EBIT (29.8x coverage).

Balance Sheet

Discover healthy companies


What is Repligen current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Repligen Dividend Yield vs Market
How does Repligen dividend yield compare to the market?
SegmentDividend Yield
Company (Repligen)n/a
Market Bottom 25% (US)1.6%
Market Top 25% (US)4.6%
Industry Average (Life Sciences)0.3%
Analyst forecast in 3 Years (Repligen)0%

Notable Dividend: Unable to evaluate RGEN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate RGEN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if RGEN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if RGEN's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as RGEN has not reported any payouts.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Tony Hunt (58 yo)





Mr. Anthony J. Hunt, also known as Tony, serves as Director at 908 Devices Inc. since March 2, 2022. He has been the Chief Executive Officer and President of Repligen Corporation since May 21, 2015. Mr. Hu...

CEO Compensation Analysis

Tony Hunt's Compensation vs Repligen Earnings
How has Tony Hunt's remuneration changed compared to Repligen's earnings?
DateTotal Comp.SalaryCompany Earnings
Jun 30 2022n/an/a


Mar 31 2022n/an/a


Dec 31 2021US$8mUS$761k


Sep 30 2021n/an/a


Jun 30 2021n/an/a


Mar 31 2021n/an/a


Dec 31 2020US$5mUS$725k


Sep 30 2020n/an/a


Jun 30 2020n/an/a


Mar 31 2020n/an/a


Dec 31 2019US$4mUS$685k


Sep 30 2019n/an/a


Jun 30 2019n/an/a


Mar 31 2019n/an/a


Dec 31 2018US$14mUS$600k


Sep 30 2018n/an/a


Jun 30 2018n/an/a


Mar 31 2018n/an/a


Dec 31 2017US$3mUS$550k


Sep 30 2017n/an/a


Jun 30 2017n/an/a


Mar 31 2017n/an/a


Dec 31 2016US$3mUS$500k


Sep 30 2016n/an/a


Jun 30 2016n/an/a


Mar 31 2016n/an/a


Dec 31 2015US$2mUS$404k


Compensation vs Market: Tony's total compensation ($USD7.77M) is below average for companies of similar size in the US market ($USD13.04M).

Compensation vs Earnings: Tony's compensation has increased by more than 20% in the past year.

Leadership Team

Experienced Management: RGEN's management team is considered experienced (4.2 years average tenure).

Board Members

Experienced Board: RGEN's board of directors are considered experienced (6.6 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: RGEN insiders have only sold shares in the past 3 months.

Recent Insider Transactions

NasdaqGS:RGEN Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
09 Sep 22SellUS$176,057Karen DawesIndividual775US$227.17
08 Sep 22SellUS$3,699,359Anthony HuntIndividual16,402US$227.01
16 Aug 22SellUS$678,593Jon SnodgresIndividual2,681US$253.16
11 Aug 22SellUS$213,478Ralf KuriyelIndividual840US$254.14
04 Aug 22SellUS$815,785Christine GebskiIndividual3,357US$243.01
21 Jul 22SellUS$929,600Anthony HuntIndividual4,648US$200.00
25 May 22SellUS$2,214,819Karen DawesIndividual14,715US$152.84
01 Mar 22SellUS$197,580Thomas RyanIndividual1,000US$197.58
18 Nov 21SellUS$2,048,227Anthony HuntIndividual7,355US$281.40
04 Nov 21SellUS$288,000Thomas RyanIndividual1,000US$288.00
02 Nov 21SellUS$729,467Karen DawesIndividual2,400US$306.49
29 Oct 21SellUS$103,748Nicholas BarthelemyIndividual360US$288.19

Ownership Breakdown

What is the ownership structure of RGEN?
Owner TypeNumber of SharesOwnership Percentage
State or Government29,9240.05%
General Public119,7710.2%
Individual Insiders3,721,8326.7%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 72.17% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
BlackRock, Inc.
T. Rowe Price Group, Inc.
The Vanguard Group, Inc.
Roy Eddleman
3,500,000$747.4m0%no data
Invesco Ltd.
Brown Capital Management, LLC
State Street Global Advisors, Inc.
WCM Investment Management, LLC
Columbia Management Investment Advisers, LLC
Artisan Partners Limited Partnership
AllianceBernstein L.P.
Franklin Resources, Inc.
BNY Mellon Asset Management
Impax Asset Management Group plc
Macquarie Investment Management Business Trust
12 West Capital Management LP
William Blair Investment Management, LLC
Conestoga Capital Advisors, LLC
Geode Capital Management, LLC
Echo Street Capital Management, LLC
Fred Alger Management, LLC
Stephens Investment Management Group, LLC
Norges Bank Investment Management
Allspring Global Investments, LLC
Point72 Asset Management, L.P.

Company Information

Repligen Corporation's employee growth, exchange listings and data sources

Key Information

  • Name: Repligen Corporation
  • Ticker: RGEN
  • Exchange: NasdaqGS
  • Founded: 1981
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$11.850b
  • Shares outstanding: 55.49m
  • Website:

Number of Employees


  • Repligen Corporation
  • Building 1
  • Suite 100
  • Waltham
  • Massachusetts
  • 2453
  • United States


TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
RGENNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDApr 1986
RGNDB (Deutsche Boerse AG)YesCommon StockDEEURApr 1986
R2GE34BOVESPA (Bolsa de Valores de Sao Paulo)BDR EACH 30 REPR 1 COMBRBRLJan 2022

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/10/04 00:00
End of Day Share Price2022/10/04 00:00
Annual Earnings2021/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.